Several cancers underrepresented in clinical trials

April 18, 2011, University of Sydney

(PhysOrg.com) -- Several cancers with a high burden of disease are not receiving the clinical trial investment they require, according to a University of Sydney study.

Several cancers with a high burden of disease are not receiving the clinical trial investment they require, according to a University of Sydney study published this week in the Medical Journal of Australia.

"Four of the five cancers that result in the greatest burden of disease had relatively few : lung, colorectal, prostate and pancreatic cancers," said Dr Rachel Dear, a medical oncologist and PhD candidate at the University of Sydney.

Dr Dear and her coauthors explored the association between clinical trial activity, burden of disease and sponsorship sources.

"We found that the number of trials for each did not always match the burden of disease caused by that cancer, thereby identifying gaps in cancer trials research," Dr Dear said.

Of 386 interventional cancer trials open to recruitment in Australia, breast cancer accounted for 62 trials. Yet only 24 trials were being conducted on lung cancer, despite it being responsible for the greatest burden of disease.

Dr Dear found that industry sponsorship is more likely for randomised controlled trials that investigate systemic therapies (drugs or biological agents) for patients with advanced cancers.

"Clinical trial registries are a largely untapped resource to describe the clinical research landscape and guide future trial activity," she said.

In an accompanying editorial, Professor Ian Olver of the Cancer Council Australia, said the study reflected the international situation, where investment in trials for specific cancer types does not correlate with the disease burden caused by those cancers.

Data from clinical trial registries have many applications. Clinicians and patients can search for trial options for specific conditions when standard treatments have been exhausted, or where no effective treatment exists, Professor Olver said.

"Data from clinical trial registries should be used to monitor the progress of such efforts to ensure Australia has a robust clinical trial capability."

More information: www.mja.com.au/

Related Stories

Recommended for you

T-cells engineered to outsmart tumors induce clinical responses in relapsed Hodgkin lymphoma

January 16, 2018
WASHINGTON-(Jan. 16, 2018)-Tumors have come up with ingenious strategies that enable them to evade detection and destruction by the immune system. So, a research team that includes Children's National Health System clinician-researchers ...

Researchers identify new treatment target for melanoma

January 16, 2018
Researchers in the Perelman School of Medicine at the University of Pennsylvania have identified a new therapeutic target for the treatment of melanoma. For decades, research has associated female sex and a history of previous ...

More evidence of link between severe gum disease and cancer risk

January 16, 2018
Data collected during a long-term health study provides additional evidence for a link between increased risk of cancer in individuals with advanced gum disease, according to a new collaborative study led by epidemiologists ...

Researchers develop a remote-controlled cancer immunotherapy system

January 15, 2018
A team of researchers has developed an ultrasound-based system that can non-invasively and remotely control genetic processes in live immune T cells so that they recognize and kill cancer cells.

Dietary fat, changes in fat metabolism may promote prostate cancer metastasis

January 15, 2018
Prostate tumors tend to be what scientists call "indolent" - so slow-growing and self-contained that many affected men die with prostate cancer, not of it. But for the percentage of men whose prostate tumors metastasize, ...

Pancreatic tumors may require a one-two-three punch

January 15, 2018
One of the many difficult things about pancreatic cancer is that tumors are resistant to most treatments because of their unique density and cell composition. However, in a new Wilmot Cancer Institute study, scientists discovered ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.